Gene therapy for children with sickle cell disease approved by FDA
Summary
The U.S. Food and Drug Administration (FDA) has approved a new gene therapy treatment for children aged 2 and older who have sickle cell disease. This treatment aims to help manage the disease by targeting its root cause.Key Facts
- The FDA approved a gene therapy for sickle cell disease in children aged 2 and above.
- Sickle cell disease is a genetic disorder that affects red blood cells.
- Gene therapy works by changing the genes to treat or prevent disease.
- This marks a new option for young patients with sickle cell disease.
- The approval is part of efforts to improve care and outcomes for children with this illness.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
